CTOs on the Move

Precision IBD

www.precisionibd.com

 
Precision IBD, Inc. is a biopharmaceutical company focused on the discovery an development of a broad portfolio of precision therapeutics and companion diagnostics for inflammatory bowel disease.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Dalton Pharma Services

Dalton Pharma Services is a North York, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genitope Corporation

Genitope Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Anox Kaldnes Inc

Anox Kaldnes Inc is a Providence, RI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Minaris Advanced Therapies

Minaris Regenerative Medicine is a global Contract Development and Manufacturing Organization (CDMO) with over 25 years of experience in cell and gene therapies. The company operates advanced facilities across North America, Europe, and Asia, providing comprehensive solutions for advanced therapy medicinal products (ATMPs). Minaris specializes in clinical and commercial manufacturing, process development, and technology transfer, ensuring compliance with regulatory standards in the U.S., EU, and Japan. The company offers a range of services, including GMP manufacturing for cell therapies, technology transfer, and clinical development support for Phase I-III trials. Minaris has successfully completed over 100 technology transfers and has recently commercialized LYFGENIA, a gene therapy for sickle cell disease. With a focus on collaboration, Minaris serves over 180 biotech and pharmaceutical clients, providing tailored solutions for their specific needs in regenerative medicine. Its facilities include expanded cleanroom capacity and analytical labs to support large-scale production.